<DOC>
	<DOCNO>NCT03079427</DOCNO>
	<brief_summary>There proven adjuvant treatment curative surgical resection patient cholangiocarcinoma , although previous meta-analysis suggest potential survival benefit adjuvant chemotherapy radiotherapy patient lymph node-positive resect cholangiocarcinoma . Despite lack level 1 evidence data regimen optimal , adjuvant chemotherapy widely use daily practice set . Based background , investigator design randomized phase 2 trial compare capecitabine gemcitabine plus cisplatin patient resect lymph node-positive extrahepatic cholangiocarcinoma .</brief_summary>
	<brief_title>Adjuvant Capecitabine v Gemcitabine Plus Cisplatin Resected Extrahepatic Cholangiocarcinoma</brief_title>
	<detailed_description />
	<mesh_term>Cholangiocarcinoma</mesh_term>
	<mesh_term>Biliary Tract Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<criteria>Patients age 19 year old Histologically document extrahepatic cholangiocarcinoma ( perihilar distal bile duct tumor ) Microscopic macroscopic surgical resection ( ie. , R0 R1 resection ) Regional lymph node metastasis accord American Joint Committee Cancer ( AJCC ) 7th edition No distant metastasis Eastern Cooperative Oncology Group ( ECOG ) performance status 0 ~ 1 No prior chemotherapy radiotherapy Serum CA 199 &lt; 100 U/mL time enrollment Adequate bone marrow function define platelet ≥ 100 x 109/L neutrophil ≥ 1.5 x 109/L Adequate renal function , serum creatinine &lt; 1.5 x upper limit normal ( ULN ) Adequate hepatic function serum total bilirubin &lt; 2 mg/dL , alanine aminotransferase ( ALT ) aspartate aminotransferase ( AST ) &lt; 2.5 x ULN No malignant disease apart nonmelanotic skin cancer carcinoma situ uterine cervix non lifethreatening cancer ( i.e. , prostate thyroid cancer ) except treat curative intent &gt; 5 year previously without evidence relapse Written inform consent study Medical psychiatric condition compromise patient 's ability give inform consent complete protocol history noncompliance Histologies adenocarcinoma mixed hepatocellular carcinoma/cholangiocarcinoma , adenosquamous carcinoma mixed adenocarcinoma/neuroendocrine carcinoma Intrahepatic cholangiocarcinoma gallbladder cancer Obstruction gastrointestinal tract Active gastrointestinal bleeding Myocardial infarction within 6 month prior study medication , clinically significant heart disease ( e.g. , unstable angina , congestive heart failure uncontrolled hypertension ) Evidence severe uncontrolled systemic disease concurrent condition investigator 's opinion make undesirable patient participate study would jeopardise compliance protocol Female subject pregnant lactating , male female reproductive potential willing able employ highly effective method birth control/contraception prevent pregnancy 2 week receive study drug 3 month receive last dose study drug . A highly effective method contraception define low failure rate ( &lt; 1 % per year ) use consistently correctly .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Cholangiocarcinoma</keyword>
	<keyword>Adjuvant chemotherapy</keyword>
</DOC>